CureVac
Gianluca Quintini serves as the Senior Director of Biomarker Development and Translational Science at CureVac AG since September 2018, following a role as Associate Director of Applied Clinical Biology at Dr. Reddy's Laboratories where responsibilities included clinical development of biosimilars. Previous roles include Senior Medical Research Scientist at Protagen AG, Principal Scientist for Biomarkers at Takeda, and Biomarker Specialist at Nycomed GmbH, among others. With a solid educational foundation including a PhD in Biology from the University of Konstanz and a Laurea from the University of Milan, Gianluca has extensive experience in biomarker strategies, clinical trials, and translational medicine across various therapeutic areas.
This person is not in any teams
This person is not in any offices
CureVac
7 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.